Cencora, Inc. specializes in distributing pharmaceutical products. The group supplies generic and name-brand medications, OTC healthcare products, and home care equipment to healthcare providers (hospitals, clinics, pharmacies, physicians, etc.) located in the United States and Canada. The group also offers services to physicians and patients (support and reimbursement assistance services, prescription management services, nursing services, home injection and perfusion services, etc.).

Employees

49,000

Sector

Medical Equipment, Supplies & Distribution

Calendar

03-08 - Leerink Global Healthcare Conference

More about the company

Quotes

Date	Price	Change	Volume
13/02/26	360.83 $	+2.78%	974,999
12/02/26	351.06 $	-4.00%	2,065,522
11/02/26	365.70 $	+1.58%	1,270,644
10/02/26	360.00 $	-0.90%	1,525,260
09/02/26	363.27 $	+1.12%	1,155,147

Delayed Quote Nyse

More quotes

Income Statement and Estimates

More financial data

Analysis / Opinion

Cencora's cure-all: A dose of data and distribution

August 19, 2024 at 04:48 pm

More analyses

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

360.83USD

Average target price

403.20USD

Spread / Average Target

+11.74%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nyse Other stock markets 00:00:03 14/02/2026 +03			5-day change	1st Jan Change
360.83 ^USD	+2.96%		+0.44%	+6.83%

02-14	Cencora, Inc. Completes the Sale of $3.0 Billion Aggregate Principal Amount of the Senior Notes	CI
02-14	Cencora Closes $3 Billion Senior Notes Offering	MT

Capitalization	70.19B 59.14B 53.95B 51.5B 95.6B 6,357B 99.33B 627B 249B 3,070B 263B 258B 10,730B	P/E ratio 2026 *	25.5x	P/E ratio 2027 *	21.3x
Enterprise value	71.78B 60.48B 55.16B 52.66B 97.76B 6,501B 102B 642B 255B 3,139B 269B 264B 10,973B	EV / Sales 2026 *	0.21x	EV / Sales 2027 *	0.19x
Free-Float	35.16%	Yield 2026 *	0.66%	Yield 2027 *	0.69%

02-14	Cencora, Inc. Completes the Sale of $3.0 Billion Aggregate Principal Amount of the Senior Notes	CI
02-14	Cencora Closes $3 Billion Senior Notes Offering	MT
02-13	Barclays Adjusts Cencora Price Target to $425 From $400, Maintains Overweight Rating	MT
02-11	Cencora Prices Senior Notes	MT
02-11	Cencora, Inc. Prices $500 Million 3.950% Senior Notes Due 2029, $500 Million 4.250% Senior Notes Due 2030, $500 Million 4.600% Senior Notes Due 2033, $1.0 Billion 4.900% Senior Notes Due 2036 and $500 Million 5.650% Senior Notes Due 2056	CI
02-10	Cencora files for five-part senior notes offering size not diclosed	RE
02-10	Wells Fargo Adjusts Price Target on Cencora to $429 From $405, Maintains Overweight Rating	MT
02-10	JPMorgan Adjusts Price Target on Cencora to $419 From $417, Maintains Overweight Rating	MT
02-05	Evercore ISI Adjusts Price Target on Cencora to $420 From $440, Maintains Outperform Rating	MT
02-05	Cardinal Health boosts annual profit forecast on surging demand for specialty drugs	RE
02-05	Cardinal Health boosts annual profit forecast on surging demand for specialty drugs	RE
02-05	McKesson boosts 2026 profit forecast amid specialty drug growth	RE
02-04	Tranche Update on Cencora, Inc.'s Equity Buyback Plan announced on May 1, 2024.	CI

02-13	Barclays Adjusts Cencora Price Target to $425 From $400, Maintains Overweight Rating	MT
02-10	Wells Fargo Adjusts Price Target on Cencora to $429 From $405, Maintains Overweight Rating	MT
02-10	JPMorgan Adjusts Price Target on Cencora to $419 From $417, Maintains Overweight Rating	MT
02-05	Evercore ISI Adjusts Price Target on Cencora to $420 From $440, Maintains Outperform Rating	MT
01-29	Cencora Shares Rise After Morgan Stanley Upgrade	MT

Cencora, Inc. Stock

Equities

COR

US03073E1055

Medical Equipment, Supplies & Distribution

Valuation: Cencora, Inc.

Chart: Cencora, Inc.

Latest news: Cencora, Inc.

Last Transcript: Cencora, Inc.

Analysts' recommendations: Cencora, Inc.

Press Releases: Cencora, Inc.

News in other languages: Cencora, Inc.

Trading Cencora, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Cencora, Inc.

Other Medical Equipment, Supplies & Distribution

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysis / Opinion

Analysts' Consensus

Quarterly revenue - Rate of surprise

02-14	Cencora Closes $3.0 Billion Senior Notes Offering	BU
02-11	Cencora Prices $500 Million 3.950% Senior Notes Due 2029, $500 Million 4.250% Senior Notes Due 2030, $500 Million 4.600% Senior Notes Due 2033, $1.0 Billion 4.900% Senior Notes Due 2036 and $500 Million 5.650% Senior Notes Due 2056	BU
02-09	Chief Executives for Corporate Purpose Announces Covista Chairman and CEO Steve Beard, Cencora Inc. Former Executive Chair Steven H. Collis, and Ann Fairchild, interim President and CEO of Siemens USA Joining Board of Directors	AQ
02-04	Cencora: Fiscal Q1 Earnings Snapshot	AQ
02-04	Cencora : First Quarter 2026 Presentation	PU

01-23	Consultorio de análisis técnico : Indra, BBVA, Acerinox, Sabadell, Salesforce, Cencora, Iberdrola...
12-23	Cartera Estadounidense: Últimas compras
12-23	Wijzigingen in de VS-portefeuille
12-23	Portafoglio USA: nuovi acquisti
12-22	USA-Portfolio von MarketScreener: Neue Umschichtung

1 day	+2.96%
1 week	+0.44%
Current month	+0.45%
1 month	+3.11%
3 months	-0.31%
6 months	+22.37%
Current year	+6.83%

1 week	347.03	374.89
1 month	328.01	374.89
Current year	328.01	374.89
1 year	237.71	377.54
3 years	147.48	377.54
5 years	100.71	377.54
10 years	68.38	377.54

Manager	Title	Age	Since
Robert Mauch CEO	Chief Executive Officer	59	01/10/2024
James Cleary DFI	Director of Finance/CFO	63	09/11/2018
Pawan Verma CTO	Chief Tech/Sci/R&D Officer	50	04/11/2024

Director	Title	Age	Since
Lon Greenberg BRD	Director/Board Member	75	16/05/2013
Robert Mauch BRD	Director/Board Member	59	01/10/2024
D. Mark Durcan CHM	Chairman	64	01/10/2025

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
CENCORA, INC.	+2.96%	+0.44%	+48.72%	+129.30%	70.19B
ABBOTT LABORATORIES	+1.09%	+1.67%	-13.73%	+5.05%	196B
MEDTRONIC PLC	-1.38%	-3.31%	+7.20%	+19.29%	128B
HOYA CORPORATION	-1.12%	+6.41%	+44.01%	+105.40%	62.23B
BECTON, DICKINSON AND COMPANY	-1.08%	-16.25%	-21.76%	-27.74%	50.08B
MEDLINE INC.	-0.09%	-5.81%	-	-	37.07B
DEXCOM, INC.	+7.59%	+0.07%	-21.39%	-40.94%	26.95B
STERIS PLC	+1.69%	-1.51%	+13.23%	+27.46%	24.36B
SARTORIUS STEDIM BIOTECH	+4.01%	-1.66%	-18.25%	-49.65%	20.2B
TERUMO CORPORATION	-2.87%	-1.69%	-29.22%	+4.39%	19.4B
Average	+1.08%	+0.16%	+0.98%	+19.17%	63.4B
Weighted average by Cap.	+0.61%	+0.52%	+3.53%	+27.38%

	2026 *	2027 *
Net sales	346B 292B 266B 254B 472B 31,376B 490B 3,097B 1,229B 15,152B 1,299B 1,272B 52,957B	370B 312B 284B 271B 504B 33,494B 523B 3,306B 1,312B 16,175B 1,387B 1,358B 56,532B
Net income	2.87B 2.42B 2.21B 2.11B 3.91B 260B 4.06B 25.67B 10.19B 126B 10.77B 10.55B 439B	3.88B 3.27B 2.98B 2.85B 5.29B 352B 5.49B 34.7B 13.78B 170B 14.56B 14.26B 593B
Net Debt	1.59B 1.34B 1.22B 1.16B 2.16B 144B 2.24B 14.17B 5.63B 69.34B 5.95B 5.82B 242B	1.34B 1.13B 1.03B 980M 1.82B 121B 1.89B 11.94B 4.74B 58.42B 5.01B 4.91B 204B